• About us
• Contact

Advertisement

Product › Details

RNActive® vaccination technology

	Next higher product group	RNAi technology_o
	Status	2006-01-18 development existent
	Organisation	CureVac GmbH
	Today	CureVac AG
	Group	CureVac (Group)

Record changed: 2018-02-01

Advertisement

More documents for RNActive® vaccination technology

• [1] CureVac AG. (1/24/18). "Press Release: CureVac Expands Intellectual Property Position that Significantly Improves Protein Expression for its mRNA-Based Vaccines and Therapeutics". Tübingen....
• [2] CureVac AG. (10/23/17). "Press Release: Publication in npj Vaccines Demonstrates CureVac’s RNActive Vaccine Is Superior to Licensed Vaccines". Tübingen & Boston, MA....
• [3] CureVac AG. (10/18/17). "Press Release: Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines". Indianapolis, IN & Tübingen....
• [4] CureVac AG. (7/20/17). "Press Release: CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies". Tübingen....
• [5] CureVac AG. (6/26/17). "Press Release: CureVac Expands GMP Production Capacities for RNA Products". Tübingen....
• [6] CureVac AG. (6/13/17). "Press Release: CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines". Tübingen....
• [7] CureVac AG. (5/2/17). "Press Release: CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary". Tübingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.